$Legend Biotech(LEGN.US) plummeted by more than ten percentage points. The direct cause was a dilutive share placement—$226 million, 7.7 million ADS, priced at $29.35, significantly below the previous day's close. When such a discounted placement is announced, existing shareholders' first reaction is to vote with their feet.
Carvykti sales are actually still ramping up, and the fundamentals are not bad. However, the short-term dilution pressure outweighed the performance results, and it coincided with existing short positions, amplifying the decline. This kind of drop caused by financing rather than operations usually recovers after the sentiment is digested.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
